DES and other coronary artery disease treatment tech trends

  *   *   *
See the December 2015 report, “Global Market Opportunities in Peripheral Arterial and Venous Stents, Forecast 2020”. A $500 advance discount is available until publication.
details
  *   *   *

A steady rate of technology development in coronary stents, producing an equally steady stream of new stent market introductions, is focused on expanding aggregate stent caseload (through penetration of what would otherwise be coronary artery bypass caseload) or shifting the balance even further toward concentration of stents sales to the drug-eluting stent (DES) variety.  While unit volumes are on the rise, pricing pressures have dampened this overall market growth and will continue to put a squeeze on stent margins.  This trend has been in force for the past two years (since the late stage thrombosis scare subsided), but going forward there will be more significant forces and developments impacting the stent market, principally the emergence of novel stent technologies like bioabsorbable stents, the emergence of drug-eluting balloons and the development of other anti-restenosis or anti-atherosclerosis options.  These dynamics are the focus of the MedMarket Diligence report #C245, the post below being a brief excerpt from that report.

The evolution of the coronary stent market has been driven by manufacturers focused on expanding the use of coronary stents into new caseload as well as penetrating the market shares of competitors.

Clinicians, for their turn as gatekeepers in this effort, are guided in the adoption of stent technologies by the availability of clinical evidence supporting expansion of stent use to patients whose coronary heart disease might otherwise be addressed by coronary artery bypass graft (CABG) surgery, with their selection of the specific stent used determined (to the extent that price is not an overriding attribute) by how well each stent’s clinical data stands up under scrutiny of possible clinical complications.

Manufacturers then take a hard view of both cost and complication rates.  Below are shown the potential complications ensuing from stent implantation and which have therefore become a focus of stent technology development:

Potential Complications Related to Implantation of Cardiovascular Stents

stent-complications

Source: MedMarket Diligence report #C245, “Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017.”

Some novel stent technologies are under development by: AdvanSource Biomaterials, Allvivo Vascular, Inc., Blue Medical Devices, CeloNova BioSciences, Hexacath, InspireMD, ITGI Medical Ltd., Miami Cardiovascular Innovations (MCVI), MoBeta, Inc., Nexeon MedSystems, Inc., OrbusNeich, Palmaz Scientific, and Prescient Medical.  Other technology developments in coronary artery disease treatments, beyond stent technologies, are also addressed in report #C245.


Download report #C245, “Worldwide Coronary Stent Market, 2008-2017,” PDF — $2,850.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

Leave a Reply